ID   HL-60/ara-C [Japan 2011]
AC   CVCL_4V19
DR   cancercelllines; CVCL_4V19
DR   Wikidata; Q54889802
RX   PubMed=21290089;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 17
//
RX   PubMed=21290089; DOI=10.3892/ijo.2011.933;
RA   Negoro E., Yamauchi T., Urasaki Y., Nishi R., Hori H., Ueda T.;
RT   "Characterization of cytarabine-resistant leukemic cell lines
RT   established from five different blood cell lineages using gene
RT   expression and proteomic analyses.";
RL   Int. J. Oncol. 38:911-919(2011).
//